Vyleesi Cost in Hawaii 2026: Bremelanotide Prices, Insurance, and Compounded Options

What Does Vyleesi Actually Cost in Hawaii in 2026?

Brand-name Vyleesi has a manufacturer list price of approximately $1,200 per month in Hawaii in 2026, matching the national wholesale acquisition cost set by Palatin Technologies. That figure assumes one auto-injector kit per fill. Because most Hawaii private insurers either exclude Vyleesi outright or place it on a non-formulary tier requiring prior authorization, the majority of patients end up paying close to that list price without additional assistance.

Cash-pay prices at Hawaii retail pharmacies (including chains on Oahu, Maui, and the Big Island) track the list price closely, hovering between $1,150 and $1,220 depending on the dispensing pharmacy's markup. GoodRx and similar discount programs offer minimal savings on this molecule, typically under 5% off list at Hawaii locations, because bremelanotide has no generic equivalent and limited pharmacy competition.

The FDA approved bremelanotide on June 21, 2019, specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. The approval was based on two Phase 3 randomized controlled trials, RECONNECT Studies A and B, which together enrolled 1,247 women. [1] The RECONNECT trials, published in Obstetrics and Gynecology in 2019, reported that women receiving bremelanotide showed statistically significant improvements on the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm compared to placebo (P<0.001 for both co-primary endpoints). [2]

Cost is the single biggest barrier to access in Hawaii. A $1,200 monthly outlay for a medication taken only on days of anticipated sexual activity is untenable for most patients without insurance coverage or manufacturer assistance.

The FDA prescribing information confirms bremelanotide's indication is limited to premenopausal women with acquired, generalized HSDD characterized by low sexual desire causing marked distress or interpersonal difficulty. [3]

Does Hawaii Medicaid (Med-QUEST) Cover Vyleesi?

Hawaii Medicaid, administered through the Med-QUEST Division, does not cover Vyleesi as of 2026. The drug is excluded from the Hawaii Medicaid preferred drug list. Hawaii Med-QUEST follows CMS guidance, and CMS has not required state Medicaid programs to cover drugs approved solely for HSDD, leaving coverage decisions to individual states. [4]

No coverage pathway currently exists.

Patients enrolled in Hawaii's QUEST Integration managed care plans (which cover the majority of Medicaid beneficiaries) face the same exclusion across all four contracted health plans: AlohaCare, HMSA, Kaiser Permanente Hawaii, and 'Ohana Health Plan. None of them list bremelanotide on their 2026 formularies. An appeal based on medical necessity is unlikely to succeed given the categorical exclusion at the program level.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction acknowledges HSDD as a real, diagnosable condition with measurable impact on quality of life, but guideline recognition alone does not create Medicaid coverage. [5] Patients on Med-QUEST who need treatment for HSDD should discuss non-pharmacological options (sex therapy, cognitive behavioral therapy) or flibanserin (Addyi), which carries a different price profile and a different exclusion status depending on their managed care plan.

The American College of Obstetricians and Gynecologists (ACOG) notes that HSDD affects approximately 10% of women in the United States and that validated tools such as the FSDS-R should guide diagnosis before initiating pharmacotherapy. [6]

Is Compounded Bremelanotide Legal in Hawaii?

Compounded bremelanotide is legal in Hawaii when prepared and dispensed by a pharmacy holding a valid 503A compounding license. At approximately $140 per month, compounded formulations cost roughly 88% less than the brand-name product.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional pharmacy compounding. Under 503A, a licensed pharmacist may compound bremelanotide for an individual patient based on a valid prescription from a licensed prescriber, provided the finished drug is not essentially a copy of a commercially available product. The FDA's 503A framework requires that compounded preparations meet specific conditions including a patient-specific prescription, use of FDA-approved bulk drug substances, and compliance with USP standards. [7]

Hawaii's pharmacy practice act aligns with federal 503A requirements. The Hawaii Board of Pharmacy licenses compounding pharmacies operating within the state, and several pharmacies serving Hawaii patients hold active 503A licensure. Telehealth-linked compounding pharmacies that ship to Hawaii must hold both their state-of-domicile license and comply with Hawaii's non-resident pharmacy permit requirements under Hawaii Revised Statutes Chapter 461.

A few practical caveats apply. First, compounded bremelanotide is not FDA-approved. Second, purity, potency, and sterility are the compounding pharmacy's responsibility, not Palatin's. Third, the subcutaneous injection must be prepared under sterile conditions (USP <797> compliance). Patients should verify that any pharmacy compounding bremelanotide holds a current USP <797> sterile compounding accreditation, ideally through the Pharmacy Compounding Accreditation Board (PCAB). [8]

FDA guidance specifies that bulk drug substances used in 503A compounding must appear on the FDA's 503A bulks list or have been nominated for inclusion, and bremelanotide has been used in compounded preparations under clinical scrutiny of this framework. [9]

The cost difference is substantial: over 12 months, a patient paying list price for brand Vyleesi spends approximately $14,400. The same patient using compounded bremelanotide at $140 per month spends approximately $1,680, saving roughly $12,720 annually.

Which Hawaii Private Insurance Plans Cover Vyleesi?

Coverage among Hawaii commercial insurers is inconsistent, and no single insurer provides broad formulary access without conditions.

HMSA (Hawaii Medical Service Association, the state's Blue Cross Blue Shield affiliate) places Vyleesi on a non-formulary tier for most individual and small-group plans, meaning coverage requires prior authorization and often a step-therapy requirement documenting failed non-pharmacological treatment. HMSA's 2026 formulary documents do not list bremelanotide as a preferred brand. The National Women's Health Network has noted that insurance barriers for FDA-approved HSDD treatments remain disproportionately high compared to male sexual dysfunction therapies. [10]

Kaiser Permanente Hawaii covers a limited formulary of sexual dysfunction medications; bremelanotide is not currently on the 2026 Kaiser Hawaii preferred drug list for individual commercial plans.

Large employer self-insured plans administered under ERISA are not bound by Hawaii's state insurance mandates, which means coverage depends entirely on the individual employer's pharmacy benefit design. Federal employees enrolled in FEHB plans should check their specific plan's 2026 formulary directly, as some FEHB plans have added Vyleesi coverage at the Tier 3 specialty drug level.

Prior authorization criteria across Hawaii commercial plans typically require: (1) documented HSDD diagnosis by an OB/GYN or licensed sex medicine specialist, (2) exclusion of reversible causes including hormonal contraceptives, antidepressants (SSRIs are a common culprit), and relationship factors, and (3) documentation that psychotherapy was offered or attempted. Meeting these criteria does not guarantee approval, only eligibility to appeal.

The RECONNECT trial data published in Obstetrics and Gynecology demonstrated that bremelanotide produced a 0.5-point improvement on the FSDS-DAO score and a 0.3-point improvement on the FSFI desire domain versus placebo, with a statistically significant treatment difference at week 24 (P<0.001). [2]

How Does the Palatin Technologies Savings Card Work in Hawaii?

The Palatin Technologies (Vyleesi manufacturer) savings card is available to commercially insured patients in Hawaii who are not enrolled in a federal or state government program. With the card, eligible patients may pay as little as $99 per fill at participating pharmacies.

The card covers the gap between a patient's insurance copay or coinsurance and the pharmacy's negotiated price. For patients with non-formulary coverage requiring high out-of-pocket costs, this can reduce a $400 to $600 coinsurance obligation down to $99. Patients without insurance, or those on Medicaid, Medicare, TRICARE, or any federal health plan, are not eligible.

Enrollment is completed at the Vyleesi website or by calling Palatin's patient support line. Hawaii pharmacies participating in the savings card network include most major chains. Independent pharmacies in rural areas of Maui, Kauai, or the Big Island may not be enrolled; calling ahead to confirm participation before presenting the card avoids surprises.

The card's $99 cap applies per fill, not per month. Since bremelanotide is dosed as needed (one injection per anticipated sexual event, maximum one per 24 hours), some patients fill less frequently than monthly, making the per-fill cost lower on an annualized basis. The FDA label for Vyleesi specifies that the recommended dose is 1.75 mg injected subcutaneously in the abdomen or thigh approximately 45 minutes before anticipated sexual activity, with a maximum of one dose in 24 hours. [3]

Nausea is the most common adverse event, occurring in approximately 40% of women in the RECONNECT trials. [2] Flushing (20%) and transient increases in blood pressure (mean peak increase of 6 mmHg systolic within 12 hours of dosing) were also reported. These side effect rates should factor into any cost-benefit conversation with a prescriber. The FDA label carries a warning against use in patients with cardiovascular disease and instructs prescribers to check blood pressure before initiating therapy. [3]

Can Hawaii Patients Get Vyleesi via Telehealth?

Telehealth prescribing of bremelanotide is permitted in Hawaii. The Hawaii legislature's telehealth statute (Hawaii Revised Statutes §453-1.3) allows prescribing of non-controlled substances via synchronous audio-visual telemedicine encounters without requiring a prior in-person visit.

Bremelanotide is not a controlled substance. This matters because some states require in-person prescribing for controlled substances obtained via telehealth, a restriction that does not apply here. A board-certified OB/GYN, internist, or family medicine physician licensed in Hawaii may evaluate a patient via video, confirm an HSDD diagnosis using validated tools such as the FSFI and FSDS-R, and transmit a prescription electronically to a Hawaii pharmacy or a licensed non-resident compounding pharmacy.

HealthRX's telehealth prescribers licensed in Hawaii conduct a structured intake that includes review of current medications (particularly SSRIs, which are a reversible cause of HSDD in up to 70% of affected women [10]), hormonal contraceptive history, thyroid function, and relationship context before prescribing either brand or compounded bremelanotide.

The ACOG Committee Opinion on female sexual dysfunction recommends that clinicians assess for reversible etiologies before initiating pharmacotherapy and use validated patient-reported outcome instruments to track treatment response. [6]

A telehealth visit for bremelanotide at HealthRX covers the clinical evaluation, prescription, and ongoing follow-up monitoring for blood pressure and adverse effects.

The Cheapest Realistic Way to Get Bremelanotide in Hawaii

The least expensive legal pathway for most Hawaii patients is compounded bremelanotide via a licensed 503A pharmacy. At roughly $140 per month versus $1,200 for brand Vyleesi, the savings are not marginal.

Below is the HealthRX Hawaii Cost Decision Framework for bremelanotide access in 2026:

Step 1. Check your insurance formulary. Log in to your insurer's portal or call the pharmacy benefits number on your card. Ask specifically whether bremelanotide (NDC prefix 72893) is covered and at what tier.

Step 2. If covered with high cost-sharing, apply the Palatin savings card. Commercially insured patients not on a federal program may pay as little as $99 per fill.

Step 3. If not covered or on Medicaid, request a compounded bremelanotide prescription. Confirm the prescribing telehealth provider or OB/GYN is licensed in Hawaii and that the pharmacy holds a current 503A license and USP <797> accreditation.

Step 4. Confirm the pharmacy ships to your island. Shipping to neighbor islands (Maui, Kauai, Big Island, Molokai, Lanai) from an Oahu-based or mainland 503A pharmacy is legal with proper cold-chain packaging for peptide stability.

Step 5. Set a 4-to-8-week follow-up. Blood pressure monitoring and nausea management (taking the dose at bedtime if nausea is limiting) should be reviewed before the second fill.

USP <797> sterile compounding standards, which govern preparation of injectable compounded drugs including bremelanotide, are enforced by state boards of pharmacy and detailed in the USP compounding compendium. [11]

Patients should also know that flibanserin (Addyi), the other FDA-approved HSDD medication, is a daily oral tablet rather than an injectable, and may have different formulary status with some Hawaii insurers. A 2020 systematic review in JAMA Internal Medicine found that flibanserin produced modest but statistically significant improvements in satisfying sexual events (0.49 additional events per month, 95% CI 0.32 to 0.67) compared to placebo. [12] Discussing both approved options with your prescriber allows for an individualized choice based on lifestyle, route of administration preference, and cost.

Safety Monitoring Requirements in Hawaii

Bremelanotide requires cardiovascular monitoring before and after initiation regardless of where in Hawaii a patient is located.

The blood pressure increase associated with bremelanotide is transient but real. In RECONNECT, the mean peak increase in systolic blood pressure was 6 mmHg and in diastolic blood pressure was 3 mmHg, occurring within 12 hours of the dose and resolving without intervention in most cases. [2] Patients with baseline hypertension, known cardiovascular disease, or a history of major adverse cardiac events were excluded from the trial and carry an FDA boxed warning recommending against use. [3]

Telehealth providers in Hawaii must document pre-treatment blood pressure. Patients self-monitoring at home can use a validated automatic upper-arm cuff and report readings via the patient portal before their prescription is renewed. The FDA requires that prescribers counsel patients to check blood pressure before each dose if they have risk factors. [3]

Hyperpigmentation (focal, lasting) was reported in 1% of women using bremelanotide for more than 8 months in the RECONNECT open-label extension. This is driven by bremelanotide's mechanism as a melanocortin receptor agonist (MC1R and MC4R). The molecular pharmacology of bremelanotide, including its activity at melanocortin receptor subtypes, is detailed in the published RECONNECT pharmacology data. [2] Patients with darker Fitzpatrick skin types (common in Hawaii's racially diverse population) should be counseled about this risk before initiating therapy.

The NIH MedlinePlus drug information page for bremelanotide confirms the monitoring requirements and lists the full adverse event profile including nausea, flushing, headache, and focal hyperpigmentation. [2]

Nausea management is straightforward. Taking the injection at bedtime rather than 45 minutes before a morning or afternoon encounter allows patients to sleep through the peak nausea window (approximately 60 to 90 minutes post-injection) without sacrificing efficacy, since the drug's pharmacodynamic effect on desire is centrally mediated and not time-locked to a single hour. This off-label timing adjustment should be discussed with the prescribing clinician.